

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 October 2024 (17.10.2024)



(10) International Publication Number
WO 2024/214016 A1

(51) International Patent Classification:

A61K 39/09 (2006.01) A61P 31/04 (2006.01)
A61K 47/64 (2017.01)

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(21) International Application Number:

PCT/IB2024/053496

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(22) International Filing Date:

10 April 2024 (10.04.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/496,045 14 April 2023 (14.04.2023) US
63/565,616 15 March 2024 (15.03.2024) US

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

(71) Applicant: **PFIZER INC.** [US/US]; 66 Hudson Boulevard
East, New York, New York 10001-2192 (US).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE

(72) Inventors: **BHETUWAL, Bishwa Raj**; c/o Pfizer Inc.,
401 N. Middletown Road, Pearl River, New York 10965
(US). **DUTTA, Kaushik**; c/o Pfizer Inc., 401 N. Middle-
town Road, Pearl River, New York 10965 (US). **GU, Jianx-
in**; c/o Pfizer Inc., 401 N. Middletown Road, Pearl River,
New York 10965 (US). **KAPIL, Sunayana**; c/o Pfizer Inc.,
401 N. Middletown Road, Pearl River, New York 10965
(US). **KIM, Jin-hwan**; c/o Pfizer Inc., 401 N. Middletown
Road, Pearl River, New York 10965 (US). **MORAN, Justin
Keith**; c/o Pfizer Inc., 401 N. Middletown Road, Pearl Riv-
er, New York 10965 (US). **SINGH, Suddham**; c/o Pfiz-
er Inc., 401 N. Middletown Road, Pearl River, New York
10965 (US). **YANG, YuYing**; c/o Pfizer Inc., 401 N. Mid-
dletown Road, Pearl River, New York 10965 (US).

(74) Agent: **ZIELINSKI, Bryan C.**; PFIZER INC., Legal Di-
vision, 66 Hudson Boulevard East, 11th Floor, New York,
New York 10001-2192 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED CAPSULAR SACCHARIDE ANTIGENS AND
USES THEREOF

(57) Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.



WO 2024/214016 A1